Morgan Stanley initiated coverage on Ashland with a new price target
$ASH
Specialty Chemicals
Consumer Discretionary
Morgan Stanley initiated coverage of Ashland with a rating of Equal-Weight and set a new price target of $60.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/15/2025 | $71.00 | Market Perform → Outperform | BMO Capital Markets |
| 9/8/2025 | $60.00 | Equal-Weight | Morgan Stanley |
| 5/1/2025 | Overweight → Equal Weight | Wells Fargo | |
| 3/26/2025 | $68.00 → $71.00 | Neutral → Overweight | Analyst |
| 3/5/2025 | Buy → Neutral | Seaport Research Partners | |
| 8/8/2024 | $90.00 → $89.00 | Underweight → Neutral | JP Morgan |
| 4/11/2024 | $100.00 → $112.00 | Equal Weight → Overweight | Wells Fargo |
| 3/14/2024 | $100.00 → $126.00 | Hold → Buy | Jefferies |
GREENWICH, Conn., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Gabelli Funds will host its 17th Annual Specialty Chemicals Symposium in Midtown Manhattan, New York City on Thursday, March 19, 2026. The event will feature discussions with leading companies and organizations across the specialty chemicals ecosystem, with an emphasis on industry dynamics, current trends, and business fundamentals, as well as Specialty Chemicals investing. Attendees will also have the opportunity to participate in one-on-one meetings with management teams, available upon request. For those who cannot attend in person, access to the symposium will be available via webcast. Investors should contact their Gabelli relations
WILMINGTON, Del., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Ashland announces the United States Environmental Protection Agency (EPA) has officially posted and approved its petition under the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA) for agrimer™ eco-coat polymer seed coating for crop care. This innovative ingredient is based on the company's patented Transformed Vegetable Oils (TVO) technology. Approval means the ingredient can now be used in all food and non‑food pesticide formulations under regulation 40 CFR 180.960. "We are pleased with the U.S. EPA posting of Ashland's latest crop care chemistry and are excited for the new opportunities this creates for collaboration with o
Sales of $386 million, down five percent from the prior-year quarterPreviously announced Avoca divestiture reduced overall sales by approximately $10 million or two percent versus the prior-year quarter; excluding the Avoca divestiture, sales declined three percentLoss from continuing operations of $14 million, or $(0.30) per diluted shareAdjusted Income from Continuing Operations Excluding Intangibles Amortization Expense of $12 million, or $0.26 per diluted shareNet loss of $12 million, or $(0.26) per diluted shareAdjusted EBITDA of $58 million, down five percent from the prior-year quarter, with the Avoca divestiture contributing to a two percent or $1 million decline; excluding the Avoca
4 - ASHLAND INC. (0001674862) (Issuer)
4 - ASHLAND INC. (0001674862) (Issuer)
4 - ASHLAND INC. (0001674862) (Issuer)
BMO Capital Markets upgraded Ashland from Market Perform to Outperform and set a new price target of $71.00
Morgan Stanley initiated coverage of Ashland with a rating of Equal-Weight and set a new price target of $60.00
Wells Fargo downgraded Ashland from Overweight to Equal Weight
SCHEDULE 13G/A - ASHLAND INC. (0001674862) (Subject)
10-Q - ASHLAND INC. (0001674862) (Filer)
8-K - ASHLAND INC. (0001674862) (Filer)
4 - ASHLAND INC. (0001674862) (Issuer)
4 - ASHLAND INC. (0001674862) (Issuer)
Sales of $386 million, down five percent from the prior-year quarterPreviously announced Avoca divestiture reduced overall sales by approximately $10 million or two percent versus the prior-year quarter; excluding the Avoca divestiture, sales declined three percentLoss from continuing operations of $14 million, or $(0.30) per diluted shareAdjusted Income from Continuing Operations Excluding Intangibles Amortization Expense of $12 million, or $0.26 per diluted shareNet loss of $12 million, or $(0.26) per diluted shareAdjusted EBITDA of $58 million, down five percent from the prior-year quarter, with the Avoca divestiture contributing to a two percent or $1 million decline; excluding the Avoca
WILMINGTON, Del., Jan. 20, 2026 (GLOBE NEWSWIRE) -- Ashland Inc. (NYSE:ASH) today announced plans to issue its first-quarter fiscal 2026 earnings release at approximately 5 p.m. ET on Monday, February 2, 2026. The company's live webcast with securities analysts will include an executive summary and detailed remarks. The live webcast will take place at 9 a.m. ET on Tuesday, February 3. Simultaneously, the company will post a slide presentation in the Investor Relations section of its website at http://investor.ashland.com. Among those participating in the webcast presentation will be: Guillermo Novo, chair, and chief executive officerWilliam Whitaker, senior vice president, and chief fina
WILMINGTON, Del., Jan. 19, 2026 (GLOBE NEWSWIRE) -- The board of directors of Ashland Inc. (NYSE:ASH) has declared a quarterly cash dividend of $0.415 cents per share on the company's common stock. The dividend will be payable on March 15, 2026, to stockholders of record at the close of business on March 1, 2026. As of December 31, 2025, there were 45,762,391 shares of Ashland common stock outstanding. About Ashland Ashland Inc. (NYSE:ASH) is a global additives and specialty ingredients company with a conscious and proactive mindset for environmental, social and governance (ESG). The company serves customers in a wide range of consumer and industrial markets, including architectural coat
SC 13G - ASHLAND INC. (0001674862) (Subject)
SC 13G/A - ASHLAND INC. (0001674862) (Subject)
SC 13D/A - ASHLAND INC. (0001674862) (Subject)
WILMINGTON, Del., May 05, 2025 (GLOBE NEWSWIRE) -- Ashland Inc. (NYSE:ASH) announced today that Kevin Willis, senior vice president and chief financial officer, has decided to leave Ashland to pursue another opportunity. His last day with the company will be May 16, 2025. Willis joined Ashland in 1987 as an associate auditor in the internal audit department. He has served in various management positions of increasing responsibility, including leading teams on major projects in the business services, information technology, accounting and finance areas. Willis' departure is not the result of any disagreement with the company related to its financial statements, internal control over finan
Turnspire Capital Partners LLC ("Turnspire") announced today that an affiliate has completed the acquisition of Pharmachem Innovations, LLC ("Pharmachem" or the "Company"), the former nutraceuticals business of Ashland Inc. (NYSE:ASH). Additionally, Turnspire Operating Partner Maurice Murphy has been appointed Executive Chairman, and Jeff Rogers has been appointed Interim Chief Executive Officer of Pharmachem. Pharmachem is a leading provider of proprietary nutrition ingredients and custom formulation services that supplies a broad portfolio of both active ingredients and formulation aids to nutritional product companies. The Company also offers custom formulation and contract manufactu
Pharmachem Innovations, LLC ("Pharmachem" or the "Company"), a leading provider of nutraceuticals products and solutions, today announced its launch as an independent company, following the acquisition of the Company from Ashland, Inc. (NYSE:ASH) by Turnspire Capital Partners LLC ("Turnspire"). Headquartered in Kearny, NJ, Pharmachem has a long history of working closely with customers around the world to develop and produce a wide range of specialized nutraceuticals. From its manufacturing facilities in New Jersey and Utah in the United States and Tamaulipas, Mexico, Pharmachem produces a wide range of proprietary and private labeled products used in many applications, including hydratio